  | DUVAL, C., STEFFEN, C., PAVIC, K., & ABANKWA, D. (28 September 2024). Protocol to measure and analyze protein interactions in mammalian cells using bioluminescence resonance energy transfer. STAR Protocols, 5 (4), 103348. doi:10.1016/j.xpro.2024.103348  Peer Reviewed verified by ORBi |
 | Lilja, J., Kaivola, J., Conway, J. R. W., Vuorio, J., Parkkola, H., Roivas, P., Dibus, M., Chastney, M. R., Varila, T., Jacquemet, G., Peuhu, E., Wang, E., Pentikäinen, U., Martinez D Posada, I., Hamidi, H., Najumudeen, A. K., Sansom, O. J., Barsukov, I. L., ABANKWA, D., ... Ivaska, J. (12 September 2024). SHANK3 depletion leads to ERK signalling overdose and cell death in KRAS-mutant cancers. Nature Communications, 15 (1), 8002. doi:10.1038/s41467-024-52326-1 Peer Reviewed verified by ORBi |
 | STEFFEN, C.* , MANOHARAN, G. B.* , PAVIC, K., Yeste-Vázquez, A., Knuuttila, M., Arora, N., Zhou, Y., Härmä, H., GAIGNEAUX, A., Grossmann, T. N., & ABANKWA, D. (09 July 2024). Identification of an H-Ras nanocluster disrupting peptide. Communications Biology, 7 (1), 837. doi:10.1038/s42003-024-06523-9 Peer Reviewed verified by ORBi* These authors have contributed equally to this work. |
 | CHIPPALKATTI, R.* , PARISI, B.* , Kouzi, F., LAURINI, C., Ben Fredj, N., & ABANKWA, D. (June 2024). RAS isoform specific activities are disrupted by disease associated mutations during cell differentiation. European Journal of Cell Biology, 103 (2), 151425. doi:10.1016/j.ejcb.2024.151425 Peer Reviewed verified by ORBi* These authors have contributed equally to this work. |
 | PARISI, B., Sünnen, M., CHIPPALKATTI, R., & ABANKWA, D. (10 October 2023). A flow-cytometry-based pipeline for the rapid quantification of C2C12 cell differentiation. STAR Protocols, 4 (4), 102637. doi:10.1016/j.xpro.2023.102637 Peer Reviewed verified by ORBi |
 | CHIPPALKATTI, R., PARISI, B., Kouzi, F., LAURINI, C., Ben Fredj, N., & ABANKWA, D. (2023). RAS isoform specific activities are disrupted by disease associated mutations during cell differentiation. Cold Spring Harbor Laboratory. doi:10.1101/2023.10.05.561021 |
 | MANOHARAN, G. B., STEFFEN, C., PAVIC, K., Yeste-Vázquez, A., Knuuttila, M., Arora, N., Zhou, Y., Härmä, H., GAIGNEAUX, A., Grossmann, T. N., & ABANKWA, D. (2023). Identification of an H-Ras nanocluster disrupting peptide. Cold Spring Harbor Laboratory. doi:10.1101/2023.09.07.556635 |
 | KAYA, P., SCHAFFNER-RECKINGER, E., MANOHARAN, G. B., Vukic, V., Kiriazis, A., LEDDA, M., Burgos, M., PAVIC, K., GAIGNEAUX, A., GLAAB, E., & ABANKWA, D. (2023). An improved PDE6D inhibitor combines with Sildenafil to synergistically inhibit KRAS mutant cancer cell growth. ORBilu-University of Luxembourg. https://orbilu.uni.lu/handle/10993/58308. doi:10.1101/2023.08.23.554263 |
 | PAVIC, K., Gupta, N., Omella, J. D., Derua, R., Aakula, A., Huhtaniemi, R., Määttä, J. A., Höfflin, N., Okkeri, J., Wang, Z., Kauko, O., Varjus, R., Honkanen, H., ABANKWA, D., Köhn, M., Hytönen, V. P., Xu, W., Nilsson, J., Page, R., ... Westermarck, J. (2023). Structural mechanism for inhibition of PP2A-B56α and oncogenicity by CIP2A. Nature Communications, 14 (1), 1143. doi:10.1038/s41467-023-36693-9 Peer Reviewed verified by ORBi |
 | STEFFEN, C., KAYA, P., SCHAFFNER-RECKINGER, E., & ABANKWA, D. (2023). Eliminating oncogenic RAS: back to the future at the drawing board. Biochemical Society Transactions. doi:10.1042/BST20221343 Peer Reviewed verified by ORBi |
 | Manoharan, G. B., Guzmán, C., Najumudeen, A. K., & ABANKWA, D. (2023). Detection of Ras nanoclustering-dependent homo-FRET using fluorescence anisotropy measurements. European Journal of Cell Biology. doi:10.1016/j.ejcb.2023.151314 Peer Reviewed verified by ORBi |
 | Manoharan, G. B., LAURINI, C., BOTTONE, S., BEN FREDJ, N., & ABANKWA, D. (2023). K-Ras Binds Calmodulin-Related Centrin1 with Potential Implications for K-Ras Driven Cancer Cell Stemness. Cancers. doi:10.3390/cancers15123087 Peer Reviewed verified by ORBi |
 | CHIPPALKATTI, R.* , PARISI, B.* , YACOUB KOUZI, F., BEN FREDJ EP SOUA, N., LAURINI, C., & ABANKWA, D. (2023). A medium-throughput assay to profile the impact of Ras-disease mutants and -drugs on cellular differentiation [Paper presentation]. Tumor Heterogeneity, Plasticity and Therapy (2nd edition), Leuven, Belgium. * These authors have contributed equally to this work. |
Yashar Rouzbahani, CHIPPALKATTI, R., ABANKWA, D., Anindita Dasgupta, Pablo Carravilla, & Christian Eggeling. (2023). Adaptation of microscopy for studying cell polarization. In N.A. N.A. doi:10.1117/12.2666385 |
 | KAYA, P., SCHAFFNER-RECKINGER, E., MANOHARAN, G. B., Saley, B., & ABANKWA, D. (18 October 2022). Novel High Affinity Inhibitors Of The K-Ras Trafficking Chaperone PDE6D [Paper presentation]. The Fourth RAS Initiative Symposium, Frederick, United States. Peer reviewed |
| MANOHARAN, G. B., PAVIC, K., Yeste Vazquez, A., Knuuttila, M., Grossmann, T. N., ABANKWA, D., & STEFFEN, C. (13 September 2022). Identification of a small peptide targeting the Raf/ Galectin interface to disrupt stabilised Ras signalling nanocluster [Paper presentation]. Small G proteins in cellular signalling and disease, Liverpool, United Kingdom. |
 | MANOHARAN, G. B., Okutachi, S., & ABANKWA, D. (2022). Potential of phenothiazines to synergistically block calmodulin and reactivate PP2A in cancer cells. PLoS ONE. doi:10.1371/journal.pone.0268635 Peer Reviewed verified by ORBi |
 | Cipriani, C., PIRES PACHECO, M. I., KISHK, A., Wachich, M., ABANKWA, D., SCHAFFNER-RECKINGER, E., & SAUTER, T. (2022). Bruceine D Identified as a Drug Candidate against Breast Cancer by a Novel Drug Selection Pipeline and Cell Viability Assay. Pharmaceuticals (Basel, Switzerland), 15 (2). doi:10.3390/ph15020179 Peer reviewed |
  | PAVIC, K., CHIPPALKATTI, R., & ABANKWA, D. (2022). Drug targeting opportunities en route to Ras nanoclusters. Advances in Cancer Research, 153, 63-99. doi:10.1016/bs.acr.2021.07.005 Peer Reviewed verified by ORBi |
| CHIPPALKATTI, R., Yacoub Kouzi Farah, BEN FREDJ EP SOUA, N., ABANKWA, D., & PARISI, B. (2022). PDE6D Dependent Trafficking of K-Ras to Stemness Promoting Centriolar Organelles [Paper presentation]. The Fourth RAS Initiative Symposium, Frederick, United States - Maryland. |
Rouzbahani, Y., CHIPPALKATTI, R., ABANKWA, D., Carravilla, P., & Eggeling, C. (2022). Advanced microscope studies of the cell polarization instructing activity of Ras proteins. Biophysical Journal, 121 (3), 278. doi:10.1016/j.bpj.2021.11.1350 |
 | GLAAB, E., MANOHARAN, G. B., & ABANKWA, D. (23 August 2021). A Pharmacophore Model for SARS-CoV-2 3CLpro Small Molecule Inhibitors and in Vitro Experimental Validation of Computationally Screened Inhibitors. Journal of Chemical Information and Modeling, 61 (8), 4082-4096. doi:10.1021/acs.jcim.1c00258 Peer Reviewed verified by ORBi |
 | Siddiqui, F. A., Vukic, V., Salminen, T. A., & ABANKWA, D. (2021). Elaiophylin Is a Potent Hsp90/ Cdc37 Protein Interface Inhibitor with K-Ras Nanocluster Selectivity. Biomolecules. doi:10.3390/biom11060836 Peer Reviewed verified by ORBi |
 | Ahearn, I. M., Court, H. R., Siddiqui, F., ABANKWA, D., & Philips, M. R. (2021). NRAS is unique among RAS proteins in requiring ICMT for trafficking to the plasma membrane. Life Science Alliance. doi:10.26508/lsa.202000972 Peer Reviewed verified by ORBi |
 | CHIPPALKATTI, R., & ABANKWA, D. (2021). Promotion of cancer cell stemness by Ras. Biochemical Society Transactions. doi:10.1042/BST20200964 Peer Reviewed verified by ORBi |
 | OKUTACHI, S. O., MANOHARAN, G. B., Kiriazis, A., LAURINI, C., CATILLON, M., McCormick, F., Yli-Kauhaluoma, J., & ABANKWA, D. (2021). A covalent calmodulin inhibitor as a tool to study cellular mechanisms of K-Ras-driven stemness. Frontiers in Cell and Developmental Biology. doi:10.3389/fcell.2021.665673 Peer Reviewed verified by ORBi |
 | Parkkola, H., Siddiqui, F. A., Oetken-Lindholm, C., & ABANKWA, D. (2021). FLIM-FRET Analysis of Ras Nanoclustering and Membrane-Anchorage. Methods in molecular biology (Clifton, N.J.), 2262, 233-250. doi:10.1007/978-1-0716-1190-6_13 Peer reviewed |
 | Rosenqvist, P., Sabt, A., Dyunyasheva, V., ABANKWA, D., Virta, P., & Ora, M. (2021). Stability of the Phosphotriester PDE6D Inhibitors. ChemistrySelect, 6 (3), 488 - 493. doi:10.1002/slct.202004426 Peer Reviewed verified by ORBi |
 | ABANKWA, D., & Gorfe, A. A. (November 2020). Mechanisms of Ras Membrane Organization and Signaling: Ras Rocks Again. Biomolecules, 10 (11). doi:10.3390/biom10111522 Peer Reviewed verified by ORBi |
 | Siddiqui, F. A., Alam, C., Rosenqvist, P., Ora, M., Sabt, A., MANOHARAN, G. B., Bindu, L., OKUTACHI, S. O., CATILLON, M., Taylor, T., Abdelhafez, O. M., Lönnberg, H., Stephen, A. G., Papageorgiou, A. C., Virta, P., & ABANKWA, D. (2020). PDE6D Inhibitors with a New Design Principle Selectively Block K‑Ras Activity. ACS Omega, 5 (1), 832-842. doi:10.1021/acsomega.9b03639 Peer Reviewed verified by ORBi |
 | Yurugi, H., Zhuang, Y., Siddiqui, F. A., Liang, H., Rosigkeit, S., Zeng, Y., Abou-Hamdan, H., Bockamp, E., Zhou, Y., ABANKWA, D., Zhao, W., Désaubry, L., & Rajalingam, K. (2020). A subset of flavaglines inhibits KRAS nanoclustering and activation. Journal of Cell Science, 133 (12). doi:10.1242/jcs.244111 Peer Reviewed verified by ORBi |
 | SCHOMMER, C., SAUTER, T., PANG, J., & ABANKWA, D. (2020). Proceedings of the AI4Health Lecture Series (2020) [Paper presentation]. AI4Health Lectures Series (2020), Campus Belval, University of Luxembourg, Luxembourg. |
 | Lilja, J., Jcaquement, G., Posada, I. M. D., Laasola, P., Vesilahti, E.-M., Miihkinen, M., Salomaa, S., Kreienkamp, H.-J., Barsukov, I., & ABANKWA, D. (2020). SHANK3 in oncogenic RAS signaling. Molecular Cancer Research. Peer Reviewed verified by ORBi |
 | Siddiqui, F. A., Parkkola, H., MANOHARAN, G. B., & ABANKWA, D. (2019). Medium-Throughput Detection of Hsp90/Cdc37 Protein–Protein Interaction Inhibitors Using a Split Renilla Luciferase-Based Assay. SLAS Discovery. doi:10.1177/2472555219884033 Peer reviewed |
 | MANOHARAN, G. B., Kopra, K., Eskonen, V., Harma, H., & ABANKWA, D. (February 2019). High-throughput amenable fluorescence-assays to screen for calmodulin-inhibitors. Analytical Biochemistry, 572, 25-32. doi:10.1016/j.ab.2019.02.015 Peer Reviewed verified by ORBi |
 | Buehler, U., Schulenburg, K., Yurugi, H., Solman, M., ABANKWA, D., Ulges, A., Tenzer, S., Bopp, T., Thiede, B., Zipp, F., & Rajalingam, K. (2018). Targeting prohibitins at the cell surface prevents Th17-mediated autoimmunity. The EMBO journal, 37 (16). doi:10.15252/embj.201899429 Peer reviewed |
Posada, I. M., Lectez, B., Siddiqui, F., Oetken-Lindholm, C., Sharma, M., Yetukuri, L., Zhou, Y., Aittokallio, T., & ABANKWA, D. (2018). PO-092 Inhibition of the mTORC1-pathway can feedback-activate H-RAS or K-RAS. ESMO Open, 3, 57. doi:10.1136/esmoopen-2018-EACR25.134 |
Lilja, J., Jacquemet, G., Posada, I. M. D., Laasola, P., Vesilahti, E., Miihkinen, M., Salomaa, S., Kreienkamp, H., Barsukov, I., & ABANKWA, D. (2018). SHANK3 in oncogenic RAS signaling [Paper presentation]. Cancer conference. |
 | Sahlgren, C., Meinander, A., Zhang, H., Cheng, F., Preis, M., Xu, C., Salminen, T., Toivola, D., ABANKWA, D., Rosling, A., Karaman, D., Salo-Ahen, O., Österbacka, R., Eriksson, J., Willför, S., Petre, I., Peltonen, J., Leino, R., Johnson, M., ... Sandler, N. (2017). Tailored Approaches in Drug Development and Diagnostics: From Molecular Design to Biological Model Systems. Advanced Healthcare Materials. doi:10.1002/adhm.201700258 Peer Reviewed verified by ORBi |
 | Posada, I., Lectez, B., Siddiqui, F., Oetken-Lindholm, C., Sharma, M., & ABANKWA, D. (2017). Opposite feedback from mTORC1 to H-ras and K-ras4B downstream of SREBP1. Scientific Reports. doi:10.1038/s41598-017-09387-8 Peer Reviewed verified by ORBi |
 | Posada, I., Lectez, B., Sharma, M., Oetken-Lindholm, C., Yetukuri, L., Zhou, Y., Aittokallio, T., & ABANKWA, D. (04 July 2017). rapalogs can promote cancer cell stemness in vitro in a Galectin-1 and H-ras-dependent manner. Oncotarget, Vol. 8 ((No. 27)), 44550-44566. doi:10.18632/oncotarget.17819 Peer Reviewed verified by ORBi |
